Back to List View Graph View

Cluster of Differentiation 28 (CD28)

CD28 (Cluster of Differentiation 28) is a co-stimulatory receptor expressed predominantly on the surface of T lymphocytes, encoded by the CD28 gene in humans.

Where the papers sit

10 papers from the last 6 months study Cluster of Differentiation 28 (CD28) directly · updated from PubMed 16 Nov 2026

  • CD28 Costimulation in Cancer Immunotherapy

    PD-1 blockade is being paired with CD28-directed strategies to strengthen or restore antitumor T-cell activity. Signaling condensates and PD-1 counter-regulation define a recurring mechanistic framework. CAR costimulatory domains, CD28 PET imaging, tumor-targeted CD28 siRNA, and HER2×CD3×CD28 engagers extend this approach from biomarker selection to treatment. Whether these combinations improve response without amplifying immune toxicity remains open.

    5 papers · 50%

  • CD28 CAR-T in T-Cell Malignancies

    CD28-containing CAR-T cells are being refined for T-lineage malignancies, especially CD7-positive T-cell acute lymphoblastic leukemia. C-terminal CD28 phosphorylation at pY218 links receptor design to IL-2 secretion and antitumor efficacy. The work is moving beyond simply adding CD28 toward tuning its intracellular signaling architecture. Durability, safety, and validation across T-cell malignancy models remain open.

    2 papers · 20%

  • Others — Computational CD28 Modulator Discovery

    AI-guided screening is identifying candidate CD28 binders and broader immune-checkpoint modulators. Prospective HTS-Oracle validation points toward combining virtual screening with experimental confirmation rather than relying on prediction alone. TIGIT, LAG3, and ICOS recur as neighboring immunotherapy targets, but no shared drug or mechanism is established. A melanoma VIP-associated gene signature sits apart, so the cluster does not support a unified therapeutic direction.

    3 papers · 30%

PARADIGM SHIFT

AI-guided screening makes direct small-molecule targeting of CD28 tractable

The AI-Enforced Ultra-Large Virtual Screening study of CD28 binders and the HTS-Oracle v2 study of CD28 among immune-checkpoint targets 42273851Jun 42440345Jul overturn the assumption that CD28, as a protein–protein-interaction target with difficult binding surfaces, is poorly accessible to small-molecule discovery. The former identified multiple direct binders, including submicromolar leads, from an AI-guided screen, while the latter obtained a 16% validated hit rate by selecting only 25 compounds for testing. Together, they indicate that AI-guided virtual and high-throughput screening can make direct CD28 small-molecule modulation a practical discovery strategy rather than an intrinsically low-yield approach.

NEW DIRECTION

CD28 is identified as a cancer-cell-intrinsic RNA-binding regulator of PD-L1

The tumor-specific CD28-siRNA lipid-nanoparticle study in anti-PD-1-resistant tumors 42261788Jun assigns CD28 a role outside the set’s usual T-cell costimulatory, immunotherapy-target, biomarker, or imaging categories: cancer-cell-intrinsic CD28 acts as a non-classical RNA-binding protein that stabilizes PD-L1 mRNA. Tumor-selective delivery of CD28 siRNA reduced cancer-cell CD28 and PD-L1 while avoiding T-cell CD28 sequestration, remodeling the immunosuppressive microenvironment and improving anti-PD-1 activity. This shifts CD28 intervention from modulating T-cell signaling to selectively silencing a tumor-cell mechanism of immune escape.

Papers

The 10 papers from the last 6 months that study Cluster of Differentiation 28 (CD28) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

CD28 Costimulation in Cancer Immunotherapy (5)
  1. CD28 costimulation is organized by signaling condensates and counteracted by PD-1. Proceedings of the National Academy of Sciences of the United States of America · 22 Oct 2026 PMID 42905561
  2. Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. Journal for immunotherapy of cancer · 7 Sept 2026 PMID 42705861
  3. Fate induction through asymmetric T cell division is modulated by chimeric antigen receptor costimulatory domains. Nature immunology · 22 Jun 2026 PMID 42332264
  4. Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261788
  5. Costimulatory biomarker-specific CD28 PET for early prediction of the response to PD-1 blockade in lung cancer. Molecular therapy : the journal of the American Society of Gene Therapy · 28 May 2026 PMID 42204816
CD28 CAR-T in T-Cell Malignancies (2)
  1. Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. Nature communications · 7 Oct 2026 PMID 42844286
  2. C-terminal CD28 phosphorylation, pY218, modulates IL-2 secretion and therapeutic effect of CAR-T cells. Molecular therapy : the journal of the American Society of Gene Therapy · 26 Aug 2026 PMID 42642932
Others — Computational CD28 Modulator Discovery (3)
  1. HTS-Oracle v2: Prospective Ai-Guided Discovery and Experimental Validation of Small Molecule Modulators Across Multiple Targets. Journal of chemical information and modeling · 13 Jul 2026 PMID 42440345
  2. AI-Enforced Ultra-Large Virtual Screening Discovers Potent CD28 Binders. Journal of chemical information and modeling · 11 Jun 2026 PMID 42273851
  3. Vasoactive intestinal peptide associated 8-gene signature with prognostic and immune associations in melanoma. Medicine · 30 May 2026 PMID 42216340

By study type

Clinical trials (1)
  1. Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. Journal for immunotherapy of cancer · 7 Sept 2026 PMID 42705861
Human data, design not indexed (3)
  1. HTS-Oracle v2: Prospective Ai-Guided Discovery and Experimental Validation of Small Molecule Modulators Across Multiple Targets. Journal of chemical information and modeling · 13 Jul 2026 PMID 42440345
  2. AI-Enforced Ultra-Large Virtual Screening Discovers Potent CD28 Binders. Journal of chemical information and modeling · 11 Jun 2026 PMID 42273851
  3. Vasoactive intestinal peptide associated 8-gene signature with prognostic and immune associations in melanoma. Medicine · 30 May 2026 PMID 42216340
Preclinical: animal, cell and lab studies (5)
  1. CD28 costimulation is organized by signaling condensates and counteracted by PD-1. Proceedings of the National Academy of Sciences of the United States of America · 22 Oct 2026 PMID 42905561
  2. Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells. Nature communications · 7 Oct 2026 PMID 42844286
  3. C-terminal CD28 phosphorylation, pY218, modulates IL-2 secretion and therapeutic effect of CAR-T cells. Molecular therapy : the journal of the American Society of Gene Therapy · 26 Aug 2026 PMID 42642932
  4. Fate induction through asymmetric T cell division is modulated by chimeric antigen receptor costimulatory domains. Nature immunology · 22 Jun 2026 PMID 42332264
  5. Costimulatory biomarker-specific CD28 PET for early prediction of the response to PD-1 blockade in lung cancer. Molecular therapy : the journal of the American Society of Gene Therapy · 28 May 2026 PMID 42204816
Unclassified: not yet indexed with MeSH (1)
  1. Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 9 Jun 2026 PMID 42261788